Suppr超能文献

COVID-19 患者中伴有和不伴有糖尿病及空腹血糖受损者纤维蛋白原升高的决定因素。

Determinants of Increased Fibrinogen in COVID-19 Patients With and Without Diabetes and Impaired Fasting Glucose.

机构信息

National Center for Trauma Medicine, Key Laboratory of Trauma and Neural Regeneration, Trauma Center, Peking University People's Hospital, Beijing, China.

出版信息

Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029621996445. doi: 10.1177/1076029621996445.

Abstract

BACKGROUND

To investigate the factors associated with elevated fibrinogen (Fbg) levels in COVID-19 patients with and without diabetes (DM) and impaired fasting glucose (IFG).

METHODS

According to whether or not their glucose metabolism was impaired, COVID-19 patients were subdivided into 2 groups: 1) with DM and IFG, 2) control group. Their demographic data, medical history, signs and symptoms, laboratory results, and final clinical results were analyzed retrospectively.

RESULTS

28 patients (16.3%) died during hospitalization, including 21 (29.2%) in group 1 and 7 (7.0%) in group 2 (P < 0.001). Fbg levels in groups 1 and 2 were higher than the normal range, at 5.6 g/L (IQR 4.5-7.2 g/L) and 5.0 g/L (IQR 4.0-6.1 g/L), respectively (P = 0.009). Serum ferritin levels, C-reactive protein (CRP), interleukin-6 (IL-6), IL-8, tumor necrosis factor-α (TNF-α), triglycerides (TG) were significantly increased in group 1 compared to those in the control. TG levels were 1.3 mmol/L in the control, while that in group 1 was 1.8 mmol/L. Multiple linear regression showed that the predicting factors of Fbg in the control group were serum ferritin and CRP, R = 0.295; in group 1, serum ferritin, CRP, and TG, R = 0.473.

CONCLUSIONS

Fbg in all COVID-19 patients is related to serum ferritin and CRP involved in inflammation. Furthermore, in COVID-19 patients with insulin resistance, Fbg is linearly positively correlated with TG. This suggests that regulation of TG, insulin resistance, and inflammation may reduce hypercoagulability in COVID-19 patients, especially those with insulin resistance.

摘要

背景

研究 COVID-19 合并糖尿病(DM)及空腹血糖受损(IFG)患者与单纯 COVID-19 患者纤维蛋白原(Fbg)升高的相关因素。

方法

根据患者血糖代谢是否受损,将 COVID-19 患者分为 2 组:1)DM 合并 IFG 组,2)对照组。回顾性分析其人口统计学资料、既往病史、临床症状、实验室检查结果及最终临床转归。

结果

28 例患者(16.3%)住院期间死亡,DM 合并 IFG 组 21 例(29.2%),对照组 7 例(7.0%)(P<0.001)。DM 合并 IFG 组和对照组 Fbg 水平均高于正常值,分别为 5.6 g/L(IQR 4.5-7.2 g/L)和 5.0 g/L(IQR 4.0-6.1 g/L)(P=0.009)。与对照组相比,DM 合并 IFG 组患者血清铁蛋白、C 反应蛋白(CRP)、白细胞介素-6(IL-6)、IL-8、肿瘤坏死因子-α(TNF-α)、三酰甘油(TG)水平显著升高,对照组 TG 为 1.3 mmol/L,DM 合并 IFG 组为 1.8 mmol/L。多元线性回归显示,对照组 Fbg 的预测因子为血清铁蛋白和 CRP,R=0.295;DM 合并 IFG 组为血清铁蛋白、CRP 和 TG,R=0.473。

结论

所有 COVID-19 患者的 Fbg 均与参与炎症的血清铁蛋白和 CRP 相关,而 COVID-19 合并胰岛素抵抗患者的 Fbg 与 TG 呈线性正相关。这提示调节 TG、胰岛素抵抗和炎症可能降低 COVID-19 患者,尤其是合并胰岛素抵抗患者的高凝状态。

相似文献

1
Determinants of Increased Fibrinogen in COVID-19 Patients With and Without Diabetes and Impaired Fasting Glucose.
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029621996445. doi: 10.1177/1076029621996445.
2
Serum triglyceride levels and related factors as prognostic indicators in COVID-19 patients: A retrospective study.
Immun Inflamm Dis. 2021 Sep;9(3):1055-1060. doi: 10.1002/iid3.469. Epub 2021 Jul 8.
3
5
Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients.
Diabetes Res Clin Pract. 2020 Jun;164:108214. doi: 10.1016/j.diabres.2020.108214. Epub 2020 May 18.
6
Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults.
Acta Diabetol. 2013 Aug;50(4):519-28. doi: 10.1007/s00592-011-0313-x. Epub 2011 Jul 16.
7
Fasting blood glucose level is a predictor of mortality in patients with COVID-19 independent of diabetes history.
Diabetes Res Clin Pract. 2020 Nov;169:108437. doi: 10.1016/j.diabres.2020.108437. Epub 2020 Sep 10.
8
Relations of hepatic steatosis with liver functions, inflammations, glucolipid metabolism in chronic hepatitis B patients.
Eur Rev Med Pharmacol Sci. 2018 Sep;22(17):5640-5646. doi: 10.26355/eurrev_201809_15830.
9
10
Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients.
Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):1042-7. doi: 10.1161/01.ATV.0000073313.16135.21. Epub 2003 Apr 24.

引用本文的文献

1
COVID-19: Not a thrombotic disease but a thromboinflammatory disease.
Ups J Med Sci. 2024 Jan 22;129. doi: 10.48101/ujms.v129.9863. eCollection 2024.
2
Diabetes and COVID-19: Role of insulin resistance as a risk factor for COVID-19 severity.
World J Diabetes. 2021 Sep 15;12(9):1550-1562. doi: 10.4239/wjd.v12.i9.1550.

本文引用的文献

1
Coronavirus-induced coagulopathy during the course of disease.
PLoS One. 2020 Dec 17;15(12):e0243409. doi: 10.1371/journal.pone.0243409. eCollection 2020.
2
Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study.
PLoS One. 2020 Dec 15;15(12):e0243604. doi: 10.1371/journal.pone.0243604. eCollection 2020.
3
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.
Lancet Haematol. 2020 Aug;7(8):e575-e582. doi: 10.1016/S2352-3026(20)30216-7. Epub 2020 Jun 30.
4
6
Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients.
Diabetes Res Clin Pract. 2020 Jun;164:108214. doi: 10.1016/j.diabres.2020.108214. Epub 2020 May 18.
7
COVID-19 update: Covid-19-associated coagulopathy.
J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3.
8
Coagulopathy in COVID-19: Manifestations and management.
Cleve Clin J Med. 2020 Jul 31;87(8):461-468. doi: 10.3949/ccjm.87a.ccc024.
9
Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19.
Cardiovasc Diabetol. 2020 May 11;19(1):58. doi: 10.1186/s12933-020-01035-2.
10
Clinical characteristics and outcomes of patients with severe covid-19 with diabetes.
BMJ Open Diabetes Res Care. 2020 Apr;8(1). doi: 10.1136/bmjdrc-2020-001343.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验